FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis

Aboul-Enein, 2006, Transient axonal injury in the absence of demyelination: a correlate of clinical disease in acute experimental autoimmune encephalomyelitis, Acta Neuropathol., 111, 539, 10.1007/s00401-006-0047-y Adelmann, 1995, The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat, J. Neuroimmunol., 63, 17, 10.1016/0165-5728(95)00124-7 Banoub, 2003, Pharmacologic and physiologic influences affecting sensory evoked potentials: implications for perioperative monitoring, Anesthesiology, 99, 716, 10.1097/00000542-200309000-00029 Bilbool, 1983, Visual evoked potentials in experimental allergic encephalomyelitis, J. Neurol. Sci., 60, 105, 10.1016/0022-510X(83)90130-2 Billich, 2003, Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases, J. Biol. Chem., 278, 47408, 10.1074/jbc.M307687200 Brinkmann, 2006, Pulmonary and vascular pharmacology of sphingosine 1-phosphate, Curr. Opin. Pharmacol., 6, 244, 10.1016/j.coph.2005.12.004 Brinkmann, 2002, The immune modulator FTY720 targets sphingosine 1-phosphate receptors, J. Biol. Chem., 277, 21453, 10.1074/jbc.C200176200 Chiba, 2006, Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus, Cell. Mol. Immunol., 3, 11 Compston, 2006, Making progress on the natural history of multiple sclerosis, Brain, 129, 561, 10.1093/brain/awl034 Cyster, 2005, Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs, Annu. Rev. Immunol., 23, 127, 10.1146/annurev.immunol.23.021704.115628 Deguchi, 1992, Electrophysiological follow-up of acute and chronic experimental allergic encephalomyelitis in the Lewis rat, Eur. Arch. Psychiatry Clin. Neurosci., 242, 1, 10.1007/BF02190335 Diem, 2003, Decreased amplitudes in multiple sclerosis patients with normal visual acuity: a VEP study, J. Clin. Neurosci., 10, 67, 10.1016/S0967-5868(02)00172-8 Dubois-Dalcq, 2005, Enhancing central nervous system remyelination in multiple sclerosis, Neuron, 48, 9, 10.1016/j.neuron.2005.09.004 Duckers, 1996, Functional and neurophysiological evidence of the efficacy of trophic pharmacotherapy using an adrenocorticotrophic hormone4–9 analog in experimental allergic encephalomyelitis, an animal model of multiple sclerosis, Neuroscience, 71, 507, 10.1016/0306-4522(95)00451-3 Duckers, 1998, Neurotrophic ACTH4–9 analogue therapy normalizes electroencephalographic alterations in chronic experimental allergic encephalomyelitis, Eur. J. Neurosci., 10, 3709, 10.1046/j.1460-9568.1998.00382.x Frohman, 2006, Multiple sclerosis—the plaque and its pathogenesis, N. Engl. J. Med., 354, 942, 10.1056/NEJMra052130 Fujino, 2003, Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment, J. Pharmacol. Exp. Ther., 305, 70, 10.1124/jpet.102.045658 Gambi, 1996, Evoked potential (EP) alterations in experimental allergic encephalomyelitis (EAE): early delays and latency reductions without plaques, Ital. J. Neurol. Sci., 17, 23, 10.1007/BF01995706 Hayreh, 1981, Experimental allergic encephalomyelitis. I: Optic nerve and central nervous system manifestations, Invest. Ophthalmol. Vis. Sci., 21, 256 Heininger, 1989, Electrophysiological investigations in adoptively transferred experimental autoimmune encephalomyelitis in the Lewis rat, Brain, 112, 537, 10.1093/brain/112.2.537 P.C. Hiestand, M. Rausch, D. Piani Meier, C.A. Foster, Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720, in: F. Petersen, R. Amstutz (Eds.), Natural Products as Drugs, Springer-Birkhäuser Verlag, Basel, Switzerland, in press. Hla, 2004, Physiological and pathological actions of sphingosine 1-phosphate, Semin. Cell Dev. Biol., 15, 513, 10.1016/j.semcdb.2004.05.002 Ishii, 2004, Lysophospholipid receptors: signaling and biology, Annu. Rev. Biochem., 73, 321, 10.1146/annurev.biochem.73.011303.073731 Jaillard, 2005, Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival, J. Neurosci., 25, 1459, 10.1523/JNEUROSCI.4645-04.2005 Jung, 2006, Pleiotropic actions of FTY720-phosphate in cells of oligodendroglial lineage, Mult. Scler., 12, S100 Kappos, 2006, Oral fingolimod (FTY720) for relapsing multiple sclerosis, N. Engl. J. Med., 355, 1124, 10.1056/NEJMoa052643 Kataoka, 2005, FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration, Cell. Mol. Immunol., 2, 439 Kerschensteiner, 2004, Remodeling of axonal connections contributes to recovery in an animal model of multiple sclerosis, J. Exp. Med., 200, 1027, 10.1084/jem.20040452 Kornek, 2000, Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions, Am. J. Pathol., 157, 267, 10.1016/S0002-9440(10)64537-3 Kutzelnigg, 2007, Widespread demyelination in the cerebellar cortex in multiple sclerosis, Brain Pathol., 17, 38, 10.1111/j.1750-3639.2006.00041.x LaMontagne, 2006, Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization, Cancer Res., 66, 221, 10.1158/0008-5472.CAN-05-2001 Lassmann, 2007, The immunopathology of multiple sclerosis: an overview, Brain Pathol., 17, 210, 10.1111/j.1750-3639.2007.00064.x Leocani, 2006, Multimodal evoked potentials to assess the evolution of multiple sclerosis: a longitudinal study, J. Neurol. Neurosurg. Psychiatry, 77, 1030, 10.1136/jnnp.2005.086280 Lublin, 2005, Multiple sclerosis trial designs for the 21st century: building on recent lessons, J. Neurol., 252, v46, 10.1007/s00415-005-5008-1 Mandala, 2002, Alteration of lymphocyte trafficking by sphingosine 1-phosphate receptor agonists, Science, 296, 346, 10.1126/science.1070238 Marburg, 1906, Die sogenannte ‘akute Multiple Sklerose’, Jahrbücher für Psychiatrie und Neurologie, 27, 211 Matloubian, 2004, Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1, Nature, 427, 355, 10.1038/nature02284 Meno-Tetang, 2006, Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses, Drug Metab. Dispos., 34, 1480, 10.1124/dmd.105.009001 Merkler, 2006, A new focal EAE model of cortical demyelination: multiple sclerosis-like lesions with rapid resolution of inflammation and extensive remyelination, Brain, 129, 1972, 10.1093/brain/awl135 Papadopoulos, 2006, Axon loss is responsible for chronic neurological deficit following inflammatory demyelination in the rat, Exp. Neurol., 197, 373, 10.1016/j.expneurol.2005.10.033 Patrikios, 2006, Remyelination is extensive in a subset of multiple sclerosis patients, Brain, 129, 3165, 10.1093/brain/awl217 Paxinos, 1998 Poliak, 2003, The local differentiation of myelinated axons at nodes of Ranvier, Nat. Rev. Neurosci., 4, 968, 10.1038/nrn1253 Rausch, 2004, Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging, J. Magn. Reson. Imaging, 20, 16, 10.1002/jmri.20057 Sanchez, 2003, Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability, J. Biol. Chem., 278, 47281, 10.1074/jbc.M306896200 Schulte, 2006, Functional hyperemic response in the rat visual cortex under halothane anesthesia, Neurosci. Lett., 394, 63, 10.1016/j.neulet.2005.10.008 Sherman, 2005, Mechanisms of axon ensheathment and myelin growth, Nat. Rev. Neurosci., 6, 683, 10.1038/nrn1743 Shriver, 2006, T-cell-mediated disruption of the neuronal microtubule network: correlation with early reversible axonal dysfunction in acute experimental autoimmune encephalomyelitis, Am. J. Pathol., 169, 999, 10.2353/ajpath.2006.050791 Stefferl, 2001, Disease progression in chronic relapsing experimental allergic encephalomyelitis is associated with reduced inflammation-driven production of corticosterone, Endocrinology, 142, 3616, 10.1210/endo.142.8.8292 Storch, 1998, Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology, Brain Pathol., 8, 681, 10.1111/j.1750-3639.1998.tb00194.x Szabó-Salfay, 2001, The electroretinogram and visual evoked potential of freely moving rats, Brain Res. Bull., 56, 7, 10.1016/S0361-9230(01)00585-8 Terai, 2003, Edg-8 receptors are preferentially expressed in oligodendrocyte lineage cells of the rat CNS, Neuroscience, 116, 1053, 10.1016/S0306-4522(02)00791-1 Toman, 2002, Lysophospholipid receptors in the nervous system, Neurochem. Res., 27, 619, 10.1023/A:1020219915922 Trip, 2005, Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis, Ann. Neurol., 58, 383, 10.1002/ana.20575 Vass, 1986, The distribution of Ia antigen in the lesions of rat acute experimental allergic encephalomyelitis, Acta Neuropathol., 70, 149, 10.1007/BF00691433 Waxman, 2006, Ions, energy and axonal injury: towards a molecular neurology of multiple sclerosis, Trends Mol. Med., 12, 192, 10.1016/j.molmed.2006.03.001 Webb, 2004, Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice, J. Neuroimmunol., 153, 108, 10.1016/j.jneuroim.2004.04.015 Weissert, 1998, MHC haplotype-dependent regulation of MOG-induced EAE in rats, J. Clin. Invest., 102, 1265, 10.1172/JCI3022 Zhang, 1991, Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation, J. Cell Biol., 114, 155, 10.1083/jcb.114.1.155